Immune Checkpoint Blockade in Cancer Therapy

Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Fo...

Full description

Bibliographic Details

Published in:	Journal of clinical oncology Vol. 33; no. 17; p. 1974
Main Authors:	Postow, Michael A, Callahan, Margaret K, Wolchok, Jedd D
Format:	Journal Article
Language:	English
Published:	United States 10.06.2015
Subjects:	Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized - pharmacology Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacology Biomarkers, Tumor CTLA-4 Antigen - antagonists & inhibitors CTLA-4 Antigen - immunology Drug Administration Schedule Humans Ipilimumab Neoplasms - drug therapy Neoplasms - immunology Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - immunology Treatment Outcome
ISSN:	1527-7755, 1527-7755
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!